1. Adelaide Research & Scholarship

Search


Current filters:




Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 31-40 of 41 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2011Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX Trial of capecitabine alone or in combination with Bevacizumab and Mitomycin in advanced colorectal cancerPrice, T.; Hardingham, J.; Lee, C.; Weickhardt, A.; Townsend, A.; Wrin, J.; Chua, A.; Shivasami, A.; Cummins, M.; Murone, C.; Tebbutt, N.
2010Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX studyTebbutt, N.; Wilson, K.; Gebski, V.; Cummins, M.; Zannino, D.; van Hazel, G.; Robinson, B.; Broad, A.; Ganju, V.; Ackland, S.; Forgeson, G.; Cunningham, D.; Saunders, M.; Stockler, M.; Chua, Y.; Zalcberg, J.; Simes, R.; Price, T.
2012Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancerWeickhardt, A.; Price, T.; Chong, G.; Gebski, V.; Pavlakis, N.; Johns, T.; Azad, A.; Skrinos, E.; Fluck, K.; Dobrovic, A.; Salemi, R.; Scott, A.; Mariadason, J.; Tebbutt, N.
2010CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: Expanded polymorphism coverage improves risk stratificationSchroth, W.; Hamann, U.; Fasching, P.; Dauser, S.; Winter, S.; Eichelbaum, M.; Schwab, M.; Brauch, H.
2011Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaPiekarz, R.; Frye, R.; Prince, H.; Kirschbaum, M.; Zain, J.; Allen, S.; Jaffe, E.; Ling, A.; Turner, M.; Peer, C.; Figg, W.; Steinberg, S.; Smith, S.; Joske, D.; Lewis, I.; Hutchins, L.; Craig, M.; Fojo, A.; Wright, J.; Bates, S.
2013The outcomes of patients with ESRD and ANCA-associated vasculitis in Australia and New ZealandTang, W.; Bose, B.; McDonald, S.; Hawley, C.; Badve, S.; Boudville, N.; Brown, F.; Clayton, P.; Campbell, S.; Peh, C.; Johnson, D.
2015Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI zlone as second-line treatment for metastatic colorectal cancerPeeters, M.; Oliner, K.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; André, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; He, P.; Yu, H.; Koukakis, R.; Terwey, J.; et al.
2013Early parenteral nutrition in critically ill patients with short-term relative contraindications to early enteral nutrition: a randomized controlled trialDoig, G.; Simpson, F.; Sweetman, E.; Finfer, S.; Cooper, D.; Heighes, P.; Davies, A.; O'Leary, M.; Solano, T.; Peake, S.
2011Sirolimus-eluting coronary stents in octogenarians: a 1-year analysis of the Worldwide e-SELECT RegistryHong, Y.; Jeong, M.; Abizaid, A.; Banning, A.; Bartorelli, A.; Dzavik, V.; Ellis, S.; Gao, R.; Holmes, D.; Legrand, V.; Neumann, F.; Spaulding, C.; Worthley, S.; Urban, P.
2017Modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukaemiaBanjar, H.; Ranasinghe, D.; Brown, F.; Adelson, D.; Kroger, T.; Leclercq, T.; White, D.; Hughes, T.; Chaudhri, N.; Speletas, M.

Discover